Arthneeti
Latest: Biocon Q1 FY27 (Apr–Jun 2026) results →This page is Q4 FY25 (Jan–Mar 2025).All Q4 FY25 results →
B

Biocon

Q4 FY25Pharmaceuticals & Biotechnology

Biocon Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Price₹416
Market cap₹67.7K Cr
P/E93.1
Updated23 Aug 2026
Read4 min read

The short version

Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).

From Biocon's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. Four biosimilars each crossed USD 200 million revenue, indicating strong adoption and future growth. (Pages 6, 13, 17)
  • Generics: Growth supported by multiple upcoming product launches including liraglutide in Europe and the U.S., generic Copaxone, Everolimus (Zortress), and continued volumes from generic lenalidomide starting FY '26. (Pages 15, 10)
  • Insulin: Significant surge in global demand with capacity doubling in Malaysia; poised to become one of the largest fully integrated insulin manufacturers. Innovators withdrawing from certain markets opens opportunities. (Pages 15, 17, 13)

2 more points from Biocon's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Biocon said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Biocon plans to spend about USD 100 million in Capex over the next couple of years, primarily to enhance biologics capacities in Malaysia (Page 14).
  • A large part of this Capex focuses on increasing insulin manufacturing capacity, including a twofold expansion of drug product and drug substance capacities in Malaysia (Page 15).
  • For Generics, next year’s Capex is estimated at around USD 50 million, mostly maintenance Capex, with major ongoing programs concluding (Page 14).

2 more points from Biocon's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Biocon said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Biocon said on order book & pipeline — free account, 30 seconds.

Biocon — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024Q3 FY25
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Biocon Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmo (Q4 FY25)

    Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…

  • Anuh Pharma (Q4 FY25)

    For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…

  • Themis Medicare (Q4 FY25)

    71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Lincoln Pharma. (Q4 FY25)

    Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Biocon and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Biocon Q4 FY25 results?

Biosimilars: Expect accelerated growth driven by new biosimilar launches with increasing market shares, e.g., Stelara and insulins expanding across 80+ countries. FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page 5,7).

What is Biocon share price analysis?

Biocon currently shows a neutral. The stock trades at a P/E of 93.1 with a market cap of ₹67,722 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon planning capital expenditure?

Biocon plans to spend about USD 100 million in Capex over the next couple of years, primarily to enhance biologics capacities in Malaysia (Page 14).

Keep Biocon on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.